{
    "clinical_study": {
        "@rank": "94079", 
        "arm_group": [
            {
                "arm_group_label": "PXVX0200", 
                "arm_group_type": "Experimental", 
                "description": "Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Biological: Placebo physiological saline"
            }
        ], 
        "brief_summary": {
            "textblock": "the purpose of the study is to determine if PXVX0200 is safe and effective in preventing\n      cholera infection"
        }, 
        "brief_title": "Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cholera", 
        "condition_browse": {
            "mesh_term": "Cholera"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy men or women,\n\n          -  age 18 to 45 years inclusive;\n\n          -  normal medical history and physical examination; and\n\n          -  no clinically significant abnormalities from:\n\n               -  urine dipstick for glucose,\n\n               -  protein, and\n\n               -  blood,\n\n               -  complete blood count,\n\n               -  serum hepatic transaminases,\n\n               -  total bilirubin (direct if abnormal),\n\n               -  creatinine,\n\n               -  electrolytes,\n\n               -  albumin, or\n\n               -  electrocardiogram.\n\n          -  Women must have a negative pregnancy test.\n\n        Exclusion Criteria:\n\n          -  travel to a cholera endemic area in the previous 5 years;\n\n          -  abnormal stool pattern or regular use of laxatives;\n\n          -  history of eating disorders (such as bulimia), anal or rectal disorders, allergy to\n             tetracycline and/or ciprofloxacin;\n\n          -  history of cholera or enterotoxigenic E. coli challenge;\n\n          -  current or recent antibiotic use;\n\n          -  pregnancy or nursing;\n\n          -  positive serology for HIV, hepatitis B antigen, or hepatitis C;\n\n          -  any immunosuppressive medical condition;\n\n          -  history of hospitalization for psychiatric illness or use of specific psychiatric\n             drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895855", 
            "org_study_id": "PXVX-VC-200-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "PXVX0200", 
                "description": "Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension", 
                "intervention_name": "PXVX0200", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland Baltimore"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229"
                    }, 
                    "name": "Cincinnati Children'S Hospital Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont", 
                        "zip": "05405"
                    }, 
                    "name": "University of Vermont"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose Live Oral Cholera Vaccine, PXVX0200 CVD 103-HgR, in Preventing Cholera Following Challenge With Vibrio Cholerae 10 Days or 3 Months After Vaccination", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Determine whether a single dose of PXVX0200 provides significant protection against a challenge with virulent V. cholerae O1 El Tor Inaba at 10 days after vaccination.", 
                "measure": "Ten day cholera challenge", 
                "safety_issue": "No", 
                "time_frame": "Ten days after vaccination"
            }, 
            {
                "description": "Determine whether a single dose of PXVX0200 provides significant protection against a challenge with virulent V. cholerae O1 El Tor Inaba at 3 months after vaccination.", 
                "measure": "Ninety day cholera challenge", 
                "safety_issue": "No", 
                "time_frame": "Ninety days after vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895855"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total weight of diarrheal stools Incidence of diarrhea of any severity Incidence of fever Incidence of fecal shedding of wild type Vibrio cholerae Peak concentration of wild type Vibrio cholerae detected in stool", 
                "measure": "disease severity", 
                "safety_issue": "No", 
                "time_frame": "from vaccination through day 180"
            }, 
            {
                "description": "Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever Incidence and severity of unsolicited adverse events", 
                "measure": "tolerability of vaccine", 
                "safety_issue": "Yes", 
                "time_frame": "following vaccination through 180 days"
            }
        ], 
        "source": "PaxVax, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PaxVax, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}